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Background: Endothelial dysfunction is an independent risk factor for cardiovascular events. Inflammatory
mediators released by the adipose tissue can lead to local insulin resistance and endothelial dysfunction. This study
addressed the relationship of adipocytokines with endothelial function and blood pressure.
Methods: In 92 newly diagnosed, drug-naïve essential hypertensive patients (HT, mean age 49 yrs) without organ
damage and 66 normotensive subjects (NT, mean age 47 yrs), by an automated system, we measured
endothelium-dependent and -independent vasodilation as brachial artery flow-mediated dilation before and after
administration of glyceryl-trinitrate. Retinol binding protein-4 (RBP4) and resistin levels were determined by ELISA
and RIA, respectively. Oxidative stress was evaluated by measuring serum malondyaldehyde (MDA).
Results: Flow-mediated dilation was significantly (p = 0.03) lower in HT (5.3 ± 2.6%) than NT (6.1 ± 3.1%), while
response to glyceryl-trinitrate (7.5 ± 3.7% vs 7.9 ± 3.4%) was similar. RBP4 (60.6 ± 25.1 vs 61.3 ± 25.9 μg/ml), resistin
(18.8 ± 5.3 vs 19.9 ± 6.1 ng/ml) and MDA levels (2.39 ± 1.26 vs 2.08 ± 1.17 nmol/ml) were not different in HT and NT.
RBP4 (r =−0.25; p = 0.04) and resistin levels (r =−0.29; p = 0.03) were related to flow-mediated dilation in NT, but not
in HT (r =−0.03 and r =−0.10, respectively). In NT, multivariate analysis including RBP4 and confounders showed
that only BMI or waist circumference remained related to flow- mediated dilation. In the multivariate model
including resistin and confounders, BMI, age and resistin were significantly related to flow-mediated dilation, while
only age significant correlated with this parameter when BMI was replaced by waist circumference.
Conclusions: Adipocytokine levels may be independent predictors of endothelial dysfunction in the peripheral
circulation of healthy subjects, providing a pathophysiological link between inflammation from adipose tissue and
early vascular alterations.
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Endothelium integrity is essential in the maintenance of
vascular homeostasis, and its dysfunction, identified as a
reduced vasodilatory response to endothelium-dependent
stimuli, predisposes to the development of early athero-
sclerotic lesions [1]. Therefore, endothelial dysfunction is
recognized as at least a marker, if not an independent risk
factor for cardiovascular events [1,2].
Although the term “dysfunction” is mainly used in
reference to a loss of nitric oxide (NO) bioavailability, it
also reflects increased production of vasoconstrictor* Correspondence: anna.solini@med.unipi.it
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reproduction in any medium, provided the oragents and disturbed regulation of inflammation, throm-
bosis and cell growth in the vascular wall [3]. All these
phenomena may identify a pathogenic link with several
chronic diseases, such as type 2 diabetes and essential
hypertension, either characterized by an early defect in
endothelial function and a certain degree of subclinical
inflammation [4].
Some inflammatory mediators originating from the
adipose tissue can lead to local insulin resistance with an
impaired inhibitory effect of insulin on the release of
free fatty acids (FFAs) and endothelial dysfunction, thus
assuming a special meaning in promoting early arterial
damage. Among these, tumor necrosis factor-α (TNFα)
has been linked with reduced insulin sensitivity andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tured endothelial cells [5], and interleukin −6 (IL-6) is
implicated in endothelial dysfunction and vascular in-
flammation through several mechanisms, including
induced expression of monocyte chemotactic protein-1
(MCP-1) [6]. More recently, retinol binding protein-4
(RBP4), an adipocytokine linked to insulin resistant
states in mouse animal models and in humans [7,8] and
predicting the development of type 2 diabetes [9], has
been associated to endothelial dysfunction in new-onset
type 2 diabetes [10]. Circulating levels of RBP4 are in-
versely related with brachial artery flow-mediated dila-
tion (FMD) in type 2 diabetic individuals [11], and RBP4
levels are also increased in other clinical conditions
characterized by increased cardiovascular risk and a cer-
tain degree of insulin resistance, such as essential hyper-
tension [12] and metabolic syndrome [13].
Another adipocytokine potentially influencing endo-
thelial function is resistin, whose plasma levels correlate
with markers of inflammation and are predictive of cor-
onary atherosclerosis in humans [14]. More recently,
resistin has been shown to induce Intercellular Adhesion
Molecule 1 (ICAM-1) and Vascular Cell Adhesion
Molecule 1 (VCAM-1) expression in endothelial cells,
thus promoting monocyte recruitment and inflammatory
responses [15].
No study has so far evaluated the relationship of these
adipocytokines with endothelial function in drug-naïve,
newly diagnosed hypertensive subjects without organ
damage and in normotensive matched individuals; the
present study has been aimed to address this specific
issue.
Subjects and methods
Patients
92 untreated neo-diagnosed, drug-naïve essential hyper-
tensive patients (HT) were consecutively recruited
among those referring to the Hypertension Outpatient
Clinic, Department of Internal Medicine of the Univer-
sity of Pisa. Exclusion criteria were diabetes mellitus
(fasting plasma glucose >126 mg/dl or pharmacologic
therapy), smoking history (more than 5 cigarettes per
day), severe hypercholesterolemia (total cholesterol
greater than 6.2 mmol/L), cardiac and/or cerebral ische-
mic vascular disease, impaired renal function, heart fail-
ure, conductance disturbances, acute inflammatory or
other major diseases. Target organ damage was excluded
according to current guidelines [16]. Sixty-six non dia-
betic normotensive subjects without family history of es-
sential hypertension and blood pressure (BP) values
below 140 and 90 mmHg, recruited on a volunteer basis,
served as controls (NT). The local Ethical Committee
approved the protocol, and all participants gave their
written informed consent.Experimental procedures
All participants were asked not to eat, and to avoid
caffeine-containing beverages, alcohol, strenuous exer-
cise and smoking for the 12 h prior to the experi-
ment. Measurements were performed in the morning
with participants supine and at rest in a quiet air-
conditioned room (22-24°C). Before starting the study,
a blood sample was drawn from an antecubital vein.
After collection, the blood was rapidly centrifuged at
1500 rpm for 5 min to separate serum and plasma
from clot-containing blood cells, storing samples at
−70 C until analysis.
Vascular function
Endothelium-dependent vasodilation was assessed as
flow-mediated dilation (FMD) of the brachial artery [17],
as previously described [18]. Briefly, after 1 min of base-
line acquisition, the cuff was inflated for 5 min and
then deflated to induce reactive hyperemia (RH).
Endothelium-independent dilation was obtained by ad-
ministration of 25 μg sublingual glyceryl trinitrate
(GTN). Brachial artery diameter was measured on
acquired frames by a computerized edge detection sys-
tem (FMD studio, Quipu s.r.l, Pisa, Italy) [19,20]. FMD
and response to GTN were calculated as the maximum
percent increase in diameter above baseline after RH
and GTN administration, respectively. Blood flow vol-
ume was calculated by multiplying Doppler flow velocity
(corrected for the angle), heart rate, and vessel cross-
sectional area (πr2) at baseline and within 15 s after cuff
release to calculate RH (as percent increase in blood
flow).
Biochemical determinations
Glucose and serum lipids were assayed by standard en-
zymatic methods. Serum creatinine was measured by the
modified Jaffe method. High-sensitive C-reactive protein
(hsCRP) was measured using a high-sensitive (low detec-
tion limit, 0.3 mg/l) immunoassay (N High Sensitivity
CRP, Dade Behring, Marburg, Germany). Estimated
glomerular filtration rate (eGFR) was calculated using
the recently developed Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation [21].
E-selectin was measured by ELISA (R&D Systems,
Abingdon, UK), with intra- and inter-assay coefficients of
variation of <5% and <10% respectively. Oxidative stress
was evaluated by measurement of plasma malondialde-
hyde (MDA) concentrations, as previously described [22],
with an intra- and inter-assay coefficient of variation (CV)
of 6% and 11%, respectively.
Plasma concentrations of RBP4 were determined by a
commercially available ELISA (R&D System GmbH,
Wiesbaden-Nordenstadt, Germany). The intraassay CV
was 4.7% and the interassay CV was 5.0%. Results were
Table 1 Clinical characteristics of the studied subjects.
Data are expressed as mean ± SD or median (range)
NT (n= 66) HT (n = 92)
Age (years) 47.1 ± 10.7 48.9 ± 9.9
Gender (male/female) 46/20 65/27
Body Mass Index (kg/m2) 26.7 ± 4.0 26.5 ± 3.9
Waist circumference (cm) 94.0 ± 11.1 94.7 ± 11.5
Smokers (yes/no) 11/55 21/71
Systolic BP (mmHg) 131.6 ± 9.0 150.9 ± 11.5*
Diastolic BP (mmHg) 81.5 ± 6.5 92.9 ± 8.5*
Fasting glucose (mg/dl) 93.6 ± 13.1 94.1 ± 12.8
Total cholesterol (mg/dl) 205.5 ± 32.1 203.3 ± 37.8
HDL cholesterol (mg/dl) 49.9 ± 14.4 52.0 ± 15.8
LDL cholesterol (mg/dl) 127.7 ± 36.7 127.8 ± 34.3
Triglycerides (mg/dl) 93 (68–147) 128 (92–174)*
Creatinine (mg/dl) 0.89 ± 0.49 0.93 ± 0.63
eGFR (ml/min/1.73 m2) 87.8 ± 11.9 84.2 ± 16.7
hsCRP (mg/l) 1.4 (0.4-3.6) 2.8 (1.3-5.9)
*p <0.05 vs normotensive patients.
HDL: High density lipoproteins; LDL: low density lipoproteins; eGFR: estimated
glomerular filtration rate.
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of ten controls and ten hypertensive patients. Briefly, sera
were diluted 1:20 in SDS-PAGE buffer and heated at 100°C
for 5 min. Samples (5 μl) and molecular weight markers
were electrophoresed on 15% Trys-Glycine SDS-PAGE gels
and transferred to PVDF membrane (Millipore, Billerica,
MA, USA). After a blocking step using BSA 3% in TTBS
(TBS and Tween-20 0.05%) for 1 h at room temperature,
blots were washed three times in TTBS and incubated
overnight at 4°C with primary antibody anti-human RBP4
(ab57620 Abcam, Cambridge, MA, USA) diluted 1:400.
The bands detection was performed incubating the blot
with horseradish-peroxidase-conjugated secondary anti-
body (AP308P Chemicon, Temecula, CA, USA) diluted
1:4000 for 1 h at room temperature, followed by enzymatic
chemiluminescence kit (34075 Pierce Biotechnology,
Rockford, IL, USA).
Plasma levels of resistin and TNFα were measured by
ELISA (R&D System, Minneapolis MN, USA; intraassay
CV 3.8% and interassay CV 6% for resistin and 10.3%
and 6.0% for TNFα, respectively).
Statistical analysis
Statistical analysis was performed using NCSS 2004
(NCSS, Kaysville, UT, USA). The results were expressed
as mean ± SD or median (range). Differences among
groups were analyzed using Student t test or Mann–
Whitney U-test. Continuous variables were compared by
Pearson's or Spearman's rank correlation coefficient.
Multiple linear regression was applied to build a model
to identify the determinants of FMD. Non-normally dis-
tributed variables were log-transformed for this analysis.
A value of p <0.05 was considered significant.
Results
Clinical characteristics of the two groups of subjects are
reported in Table 1. HT and NT did not differ for clin-
ical characteristics with the exception of BP values and
triglycerides levels; even hsCRP did not differ between
the two groups.
As expected, FMD was significantly lower in HT as
compared to NT (Figure 1), while response to GTN
(7.5 ± 3.7% vs 7.9 ± 3.4%), diameter (0.43 ± 0.09 vs
0.41 ± 1.02 cm) and peak shear rate (6.33 ± 2.78 vs
6.28 ± 2.89 s-1) were similar. In agreement with the
reduced FMD, HT also showed higher levels of the
endothelial-specific protein E-selectin (Figure 1), while
MDA levels did not differ between HT and NT
(2.39 ± 1.26 and 2.08 ± 1.17 nmol/ml, respectively). No
relationship was found between hsCRP and either FMD
and MDA levels in the two groups.
The different behaviour of FMD and E-selectin in HT
vs NT individuals was not paralleled by a concomitant
variation of adipocytokine levels: in fact, RBP4, resistinand TNFα did not differ between the two groups
(Figure 2). This was true even when we compared smo-
kers with non smokers (data not shown).
RBP4 levels were significantly related to resistin in the
overall population (r = 0.46; p <0.0001) and in NT
(r = 0.89; p <0.0001), but not in HT (r =−0.01; p = 0.97).
No relationships were found among TNFα and adipocy-
tokines levels, excluding with resistin in HT (r =−0.32;
p = 0.02).
Analyzing linear correlations between RBP4, resistin,
TNFα and the clinical parameters in NT, RBP4 was
related to diastolic BP (r = 0.25; p = 0.04) and MDA
(r = 0.28; p = 0.03), but not to BMI and-or waist circum-
ference. Resistin was related to diastolic BP (r = 0.32;
p = 0.01), log transformed triglycerides (r = 0.34; p = 0.01)
and waist circumference (r = 0.24; p = 0.04), but not with
BMI. In HT, the only significant relationship was be-
tween resistin and plasma glucose (r = 0.33, p = 0.01).
TNFα was not related with any clinical parameter, nei-
ther in NT and HT individuals. No relationship was
found between any adipocytokine and eGFR value, either
in NT and HT individuals.
We then explored the putative relationship between
cytokine levels and endothelial function. Either E-selectin
levels (a reliable proxy of endothelial activation) or re-
sponse to GTN did not correlate with FMD and RBP4 or
resistin. The only significant correlates of E-selectin were
systolic and diastolic BP in the overall population (r = 0.31
and 0.29, respectively; both p <0.001).
Figure 1 Flow mediated dilation and plasma E-selectin levels in the two study groups. Box-plots show flow mediated dilation (FMD,
expressed as percent of increase in brachial artery diameter above baseline after reactive hyperemia), and E-selectin levels in normotensive
subjects (NT, blue plots) and essential hypertensive patients (HT, green plots).
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p = 0.03) were related to FMD in NT (Figure 3), but not
in HT (r =−0.03; p = 0.81 and r =−0.10; p = 0.46, respect-
ively); other significant correlates of FMD in NT were
brachial artery diameter (r =−0.60; p <0.001), age
(r =−0.29; p = 0.02), BMI (r =−0.33; p = 0.008), waist cir-
cumference (r =−0.35; p = 0.006) and log transformed
triglycerides (r =−0.29; p = 0.02).
Multivariate analysis performed in NT, including con-
founders (age, BMI, diastolic BP, log transformed trigly-
cerides, MDA) and RBP4, showed that only BMI
remained significantly related to FMD (Table 2). Similar
results were obtained when BMI was replaced by waist
circumference. Multivariate analysis performed in NT,
including confounders (age, BMI, diastolic BP, log trans-
formed triglycerides, resistin) showed that BMI, age and
resistin were significantly related to FMD (Table 2).Figure 2 Retinol binding protein-4, resistin and TNFα levels in the tw
resistin and TNFα levels in normotensive subjects (NT, blue plots) and esseWhen BMI was replaced by waist circumference in the
model, only age remained significantly related to FMD.
Discussion
Relationship between adipocytokines and endothelial
function
RBP4 has been previously related to insulin resistance
and clinical markers of increased cardiovascular risk
such as intima-media thickness (IMT), not only in high-
risk individuals including hypertensive and type 2 dia-
betic and hypertensive patients [10,12], but also in the
general population [23]. Moreover, RBP4 levels have
been related with in vivo evaluation of endothelial func-
tion in patients with type 2 diabetes [11], but such
relation has not been explored so far in essential hyper-
tension. Reports dealing with the role of resistin during
the course of hypertension are more contradictory:o study groups. Box-plots show retinol binding protein-4 (RBP4),
ntial hypertensive patients (HT, green plots).
Figure 3 Correlation between flow mediated dilation and retinol binding protein-4 and resistin levels in normotensive subjects.
Scatter-plots of the correlation between flow mediated dilation (FMD, percent increase in brachial artery diameter) and retinol binding protein-4
(RBP4, r =−0.25; p = 0.04, left) and resistin (r =−0.29; p = 0.03, right) levels in normotensive individuals.
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creasing the expression of adhesion molecules and ET-1
release [15,24]; its plasma levels are inconstantly elevated
in patients with essential hypertension [12,25], and are
not in elderly people [26].
We show here for the first time that i) in neodiag-
nosed, drug-naïve hypertensive individuals, neither RBP4
nor resistin are related with endothelial dysfunction; ii),
vice versa, in healthy (normotensive non diabetic and
non obese) individuals, even in the presence of RBP4
and resistin levels within the normal range, a strict rela-
tionship exists between these adipocytokines and endo-
thelial function.Table 2 Adipocytokines and clinical and vascular factors
affecting flow mediated dilation in the normotensive
individuals- multivariate analysis
Model 1 r2 = 0.25 Model 2 r2 = 0.29
Factor p value Factor p value
Age 0.06 Age 0.14
BMI 0.02 Waist 0.04
Diastolic BP 0.75 Diastolic BP 0.56
Ln (triglycerides) 0.64 Ln (triglycerides) 0.55
MDA 0.81 MDA 0.75
RBP4 0.07 RBP4 0.08
Model 3 r2 = 0.29 Model 4 r2 = 0.15
Factor p value Factor p value
Age 0.03 Age 0.03
BMI 0.01 Waist 0.27
Diastolic BP 0.85 Diastolic BP 0.71
Ln (triglycerides) 0.16 Ln (triglycerides) 0.29
Resistin 0.03 Resistin 0.29
BMI: body mass index; BP: blood pressure; Ln: log-transformed; MDA:
malondialdehyde.Differences between normotensive and hypertensive
individuals
In our hands, RBP4 levels did not differ between hyper-
tensive and normotensive individuals; however, any pu-
tative influence of dietary intake on RBP4 levels [27] of
our study participants might reasonably be excluded
from personal history on life habits. This finding is par-
tially at odd with our previous published data [12],
which were, however, obtained in a cohort of women,
while the male gender was largely prevalent in both
groups of the present study population. A recent report
suggests a role of smoking in influencing RBP4 concen-
trations in Chinese healthy individuals [28]: in our Cau-
casian population (where smokers were about one fifth),
this observation was not confirmed.
We were also unable to find differences in resistin
levels between hypertensive and normotensive subjects,
as already reported in women [12]. A possible explan-
ation could be that in both studies we evaluated only
neo-diagnosed patients, with a presumably short dur-
ation of the disease and no clinically evident organ dam-
age, while resistin is elevated in patients with
inflammatory vascular damage [29] and advanced ath-
erosclerotic disease [30,31]; another possibility could be
that our patients had all a preserved kidney function,
while a reduced GFR has been linked to increased resis-
tin levels in a large cohort of community-dwelling sub-
jects [32].
Relationship between FMD, MDA and adipocytokines
Concerning endothelial function in the peripheral micro-
circulation, brachial artery FMD is reduced in hyperten-
sive as compared to normotensive subjects, confirming
previous results [18]. Since endothelium-independent
vasodilation and peak shear rate were similar, these results
indicate the presence of endothelial dysfunction; accord-
ingly, HT showed also increased levels of E-selectin, a
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that reported in patients with type 2 diabetes [10], RBP4
levels were not related to FMD in hypertensive individuals
carrying endothelial dysfunction; similarly, E-selectin did
not correlate with RBP4 in these patients. The lack of this
relationship might be that endothelial dysfunction might
recognize different mechanisms in diabetes and essential
hypertension [34]; an alternative explanation could be the
almost superimposable RBP4 concentrations between the
two groups, making impossible to pick up small differ-
ences in the correlations. However, our results might in-
directly confirm the scarce role of RBP4 as early marker
of subclinical vascular impairment, as recently documen-
ted [35]. Another potential explanation for the lack of
these correlations may be due to the fact that none of
these subjects showed any clinical sign of autonomic
neuropathy, another condition influencing plasma adipo-
cytokine concentrations, for example in type 2 diabetes
[36].
Quite surprisingly, in healthy normotensive subjects
RBP4, but not E-selectin, was significantly related to
FMD and MDA, suggesting a specific role for this adipo-
kine in marking endothelial dysfunction and oxidative
stress, but not endothelial activation. However, multi-
variate analysis revealed that, even in slim healthy indivi-
duals, indexes of adiposity (BMI or waist circumference)
remain the only independent determinants of FMD,
again underlining the possible role of RBP4 as marker of
early endothelial dysfunction, even in the absence of ex-
cess of fat depots or other CV risk factors. The possibil-
ity that arterial diameter influences the relationship
between FMD and BMI is plausible; however, since bra-
chial artery diameter is highly related with FMD, this hy-
pothesis cannot be formally tested, because its inclusion
in the model might cause statistical multicollinearity.
Role of resistin and TNFα
The relationship among resistin, hypertension and endo-
thelial function is even more complex. A direct influence
of resistin in promoting endothelial activation and influ-
encing endothelial function has been so far described
only in experimental models [24,37,38], even though
pharmacological interventions in nondiabetic hyperten-
sive individuals might reduce resistin levels in parallel
with an improvement of endothelial function [39,40].
Here, we show for the first time that, as for RBP4, no re-
lationship is present between resistin levels and in vivo
repeatable assessment of endothelial function in un-
treated essential hypertension. However, the relationship
between resistin and endothelial function in healthy
normotensive individuals without family history of
hypertension assumes a special meaning, since resistin
levels remained significant correlates of FMD also in the
multivariate analysis, independently of BMI and waistcircumference. These results could be also related to the
recent report that resistin, as already shown for reduced
FMD [41], predicts the development of hypertension in
healthy women [42].
The lack of correlation between TNFα levels and FMD
might surprise, given the relevant contribution of this
cytokine to the pathogenesis of endothelial dysfunction
[43]. This finding could be due to the fact that TNFα
mirrors the degree of subclinical inflammation, almost
absent in our study population, as shown by hsCRP
levels, relatively low either in HT and NT subjects and
not related with any marker of endothelial function.
Conclusions
Our data suggest that RBP4 and resistin might mark an
early vascular dysfunction not detected by common vas-
cular indicators like E-selectin, which is a likely indicator
of a more advanced degree of endothelial impairment.
The main limitations of this study include the small
sample size, that implies to consider the results as a sim-
ple clinical observation deserving further confirmation
in larger populations; however, these preliminary obser-
vations might provide a pathophysiological link between
inflammation from adipose tissue and early vascular
alterations.
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